INTRODUCTION {#s1}
============

To investigate Alzheimer\'s disease (AD) genetic risk factors, several genome-wide association studies (GWAS) have identified several new AD susceptibility loci in European populations, and some of these loci were successfully replicated in other studies \[[@R1]-[@R5]\]. To detect more AD genetic signals, several pathway analyses of GWAS datasets have been conducted \[[@R6]-[@R11]\]. Lambert et al. identified significant immune KEGG pathways and GO categories in AD \[[@R6]\]. Jones et al. reported significant KEGG pathways and 25 GO pathways in AD \[[@R8]\]. Most of the 25 pathways are related to metabolism \[[@R8]\]. Liu et al. highlighted the cardiovascular disease-related pathways in AD \[[@R12]\]. The International Genomics of Alzheimer\'s Project (IGAP) Consortium reported 10 significant KEGG pathways \[[@R13]\]. Until now, the potential mechanisms of these risk pathways in AD are still unclear.

We think that the different expression (up-regulation or down-regulation) of genes in these pathways may contribute to AD susceptibility. Here, we selected a whole genome AD case-control expression dataset (*n* = 41, 25 AD cases and 16 controls) from the human temporal cortex tissue, and conducted a pathway analysis using all the differently expressed AD genes, up-regulated AD genes, and down-regulated AD genes. We further compare the AD risk pathways from the expression dataset with those from previous GWAS datasets to address the potential mechanisms.

RESULTS {#s2}
=======

Pathway analysis of differently expressed AD genes {#s2_1}
--------------------------------------------------

Using 1179 differently expressed AD genes, we identified 33 significant immune and metabolic pathways with *P* \< 0.05 after FDR correction for multiple testing. These 33 pathways include 11 immune pathways and 22 metabolic pathways (Table [1](#T1){ref-type="table"}). Oxidative phosphorylation (hsa00190) and Systemic lupus erythematosus (hsa05322) are the most significant metabolic and immune pathways with adjusted *P* = 1.33E-07 and *P* = 4.00E-04, respectively.

###### significant pathways from the pathway analysis of differently expressed AD genes in expression dataset

  Classification   Pathway ID   Pathway Name                                                 C     O    E      R       rawP       adjP
  ---------------- ------------ ------------------------------------------------------------ ----- ---- ------ ------- ---------- ----------
  Immunity         hsa05322     Systemic lupus erythematosus                                 136   13   3.72   3.5     9.70E-05   4.00E-04
  Immunity         hsa05323     Rheumatoid arthritis                                         91    7    2.49   2.81    1.25E-02   1.70E-02
  Immunity         hsa04666     Fc gamma R-mediated phagocytosis                             94    9    2.57   3.5     1.10E-03   2.90E-03
  Immunity         hsa04062     Chemokine signaling pathway                                  189   13   5.17   2.52    2.20E-03   4.80E-03
  Immunity         hsa04640     Hematopoietic cell lineage                                   88    8    2.41   3.33    2.80E-03   5.50E-03
  Immunity         hsa04650     Natural killer cell mediated cytotoxicity                    136   10   3.72   2.69    4.30E-03   7.30E-03
  Immunity         hsa04670     Leukocyte transendothelial migration                         116   9    3.17   2.84    4.70E-03   7.80E-03
  Immunity         hsa04660     T cell receptor signaling pathway                            108   8    2.95   2.71    9.70E-03   1.41E-02
  Immunity         hsa04622     RIG-I-like receptor signaling pathway                        71    6    1.94   3.09    1.31E-02   1.75E-02
  Immunity         hsa04662     B cell receptor signaling pathway                            75    6    2.05   2.93    1.68E-02   2.22E-02
  Immunity         hsa04612     Antigen processing and presentation                          76    6    2.08   2.89    1.78E-02   2.29E-02
  Metabolism       hsa00190     Oxidative phosphorylation                                    132   17   3.61   4.71    1.33E-07   2.19E-06
  Metabolism       hsa00360     Phenylalanine metabolism                                     17    7    0.46   15.06   1.72E-07   2.43E-06
  Metabolism       hsa00020     Citrate cycle (TCA cycle)                                    30    7    0.82   8.54    1.32E-05   9.48E-05
  Metabolism       hsa00250     Alanine, aspartate and glutamate metabolism                  32    7    0.87   8       2.07E-05   1.00E-04
  Metabolism       hsa00830     Retinol metabolism                                           64    9    1.75   5.14    5.91E-05   3.00E-04
  Metabolism       hsa00500     Starch and sucrose metabolism                                54    8    1.48   5.42    1.00E-04   4.00E-04
  Metabolism       hsa00350     Tyrosine metabolism                                          41    7    1.12   6.25    1.00E-04   4.00E-04
  Metabolism       hsa00270     Cysteine and methionine metabolism                           36    6    0.98   6.1     4.00E-04   1.30E-03
  Metabolism       hsa00983     Drug metabolism - other enzymes                              52    7    1.42   4.92    5.00E-04   1.50E-03
  Metabolism       hsa00053     Ascorbate and aldarate metabolism                            26    5    0.71   7.03    6.00E-04   1.70E-03
  Metabolism       hsa00980     Metabolism of xenobiotics by cytochrome P450                 71    8    1.94   4.12    7.00E-04   2.00E-03
  Metabolism       hsa00982     Drug metabolism - cytochrome P450                            73    8    2      4.01    9.00E-04   2.50E-03
  Metabolism       hsa00040     Pentose and glucuronate interconversions                     32    5    0.87   5.72    1.70E-03   3.90E-03
  Metabolism       hsa00140     Steroid hormone biosynthesis                                 56    6    1.53   3.92    4.20E-03   7.30E-03
  Metabolism       hsa00620     Pyruvate metabolism                                          40    5    1.09   4.57    4.50E-03   7.60E-03
  Metabolism       hsa00380     Tryptophan metabolism                                        42    5    1.15   4.35    5.60E-03   8.90E-03
  Metabolism       hsa00860     Porphyrin and chlorophyll metabolism                         43    5    1.18   4.25    6.20E-03   9.60E-03
  Metabolism       hsa00514     Other types of O-glycan biosynthesis                         46    5    1.26   3.98    8.20E-03   1.23E-02
  Metabolism       hsa00561     Glycerolipid metabolism                                      50    5    1.37   3.66    1.16E-02   1.59E-02
  Metabolism       hsa00562     Inositol phosphate metabolism                                57    5    1.56   3.21    1.96E-02   2.49E-02
  Metabolism       hsa00010     Glycolysis / Gluconeogenesis                                 65    5    1.78   2.81    3.25E-02   3.83E-02
  Metabolism       hsa00534     Glycosaminoglycan biosynthesis - heparan sulfate / heparin   26    5    0.71   7.03    6.00E-04   1.70E-03

C, the number of reference genes in the category; O, the number of genes in the gene set and also in the category; E, expected number in the category; R, the ratio of enrichment, rawP, the *p* value from hypergeometric test; adjP, the *p* value adjusted by the multiple test adjustment.

Pathway analysis of up-regulated AD genes {#s2_2}
-----------------------------------------

Using 599 up-regulated AD genes, we identified 18 significant pathways including 6 immune and 12 metabolic pathways with *P* \< 0.05 after FDR correction for multiple testing (Table [2](#T2){ref-type="table"}). Systemic lupus erythematosus (hsa05322) and Phenylalanine metabolism (hsa00360) are the most significant immune and metabolic pathways with adjusted *P* = 1.44E-06 and *P* = 3.08E-05, respectively.

###### significant pathways from the pathway analysis of up-regulated AD genes in expression dataset

  Classification   Pathway ID   Pathway Name                                   C     O    E      R       rawP       adjP
  ---------------- ------------ ---------------------------------------------- ----- ---- ------ ------- ---------- ----------
  Immunity         hsa05322     Systemic lupus erythematosus                   136   13   1.89   6.88    6.41E-08   1.44E-06
  Immunity         hsa04670     Leukocyte transendothelial migration           116   8    1.61   4.97    2.00E-04   7.00E-04
  Immunity         hsa04640     Hematopoietic cell lineage                     88    6    1.22   4.91    1.40E-03   2.40E-03
  Immunity         hsa04650     Natural killer cell mediated cytotoxicity      136   7    1.89   3.71    3.00E-03   4.10E-03
  Immunity         hsa04666     Fc gamma R-mediated phagocytosis               94    5    1.31   3.83    1.01E-02   1.23E-02
  Immunity         hsa04660     T cell receptor signaling pathway              108   5    1.5    3.33    1.76E-02   2.03E-02
  Metabolism       hsa00360     Phenylalanine metabolism                       17    5    0.24   21.18   2.74E-06   3.08E-05
  Metabolism       hsa00500     Starch and sucrose metabolism                  54    7    0.75   9.33    9.69E-06   7.27E-05
  Metabolism       hsa00053     Ascorbate and aldarate metabolism              26    5    0.36   13.85   2.63E-05   1.00E-04
  Metabolism       hsa00830     Retinol metabolism                             64    7    0.89   7.87    3.01E-05   2.00E-04
  Metabolism       hsa00040     Pentose and glucuronate interconversions       32    5    0.44   11.25   7.51E-05   3.00E-04
  Metabolism       hsa00860     Porphyrin and chlorophyll metabolism           43    5    0.6    8.37    3.00E-04   9.00E-04
  Metabolism       hsa00350     Tyrosine metabolism                            41    5    0.57   8.78    3.00E-04   9.00E-04
  Metabolism       hsa00514     Other types of O-glycan biosynthesis           46    5    0.64   7.83    4.00E-04   1.00E-03
  Metabolism       hsa00982     Drug metabolism - cytochrome P450              73    6    1.01   5.92    5.00E-04   1.10E-03
  Metabolism       hsa00980     Metabolism of xenobiotics by cytochrome P450   71    6    0.99   6.08    5.00E-04   1.10E-03
  Metabolism       hsa00983     Drug metabolism - other enzymes                52    5    0.72   6.92    8.00E-04   1.60E-03
  Metabolism       hsa00140     Steroid hormone biosynthesis                   56    5    0.78   6.43    1.10E-03   2.10E-03

C, O, E, R, rawP, and adjP have been defined in Table [1](#T1){ref-type="table"}.

Pathway analysis of down-regulated AD genes {#s2_3}
-------------------------------------------

Using 580 down-regulated AD genes, we identified 6 significant signals including 1 immune and 5 metabolic pathways with *P* \< 0.05 after FDR correction for multiple testing (Table [3](#T3){ref-type="table"}). Chemokine signaling pathway (hsa04062) is the only significant immune pathway with adjusted *P* = 1.90E-03. Interestingly, Oxidative phosphorylation (hsa00190), the most significant signal from the pathway analysis of all differently expressed AD genes (Table [1](#T1){ref-type="table"}), is also the most significant metabolic pathway from pathway analysis of down-regulated AD genes with adjusted *P* = 2.99E-11 (Table [3](#T3){ref-type="table"}).

###### significant pathways from the pathway analysis of down-regulated AD genes in expression dataset

  Classification   Pathway ID   Pathway Name                                                 C     O    E      R       rawP       adjP
  ---------------- ------------ ------------------------------------------------------------ ----- ---- ------ ------- ---------- ----------
  Immunity         hsa04062     Chemokine signaling pathway                                  189   9    2.54   3.54    1.10E-03   1.90E-03
  Metabolism       hsa00190     Oxidative phosphorylation                                    132   17   1.78   9.58    3.15E-12   2.91E-11
  Metabolism       hsa00020     Citrate cycle (TCA cycle)                                    30    7    0.4    17.35   1.19E-07   7.47E-07
  Metabolism       hsa00250     Alanine, aspartate and glutamate metabolism                  32    6    0.43   13.94   3.88E-06   1.62E-05
  Metabolism       hsa00534     Glycosaminoglycan biosynthesis - heparan sulfate / heparin   26    5    0.35   14.3    2.25E-05   7.70E-05
  Metabolism       hsa00230     Purine metabolism                                            162   7    2.18   3.21    6.60E-03   8.20E-05

C, O, E, R, rawP, and adjP have been defined in Table [1](#T1){ref-type="table"}.

Comparing the AD immune pathways using GWAS and expression data {#s2_4}
---------------------------------------------------------------

We compared the 11 AD immune pathways with previous pathway analysis of AD GWAS. We found that 9 of the 11 pathways in Table [1](#T1){ref-type="table"} (excluding Leukocyte transendothelial migration, hsa04670 and B cell receptor signaling pathway, hsa04662) have been identified by Liu \[[@R12]\]. 4 of these 11 AD immune pathways including Natural killer cell mediated cytotoxicity (hsa04650), Antigen processing and presentation (hsa04622), RIG-I-like receptor signaling (hsa04612), and Hematopoietic cell lineage (hsa04640), have been reported \[[@R6], [@R8], [@R13]\].

Comparing the AD metabolic pathways using GWAS and expression data {#s2_5}
------------------------------------------------------------------

We compared the 22 AD metabolic pathways with previous pathway analysis of AD GWAS. We found that 10 of the 22 pathways in Table [1](#T1){ref-type="table"} have been identified \[[@R12]\], including Oxidative phosphorylation (hsa00190), Steroid hormone biosynthesis (hsa00140), Metabolism of xenobiotics by cytochrome P450 (hsa00980), Porphyrin and chlorophyll metabolism (hsa00860), Drug metabolism - cytochrome P450 (hsa00982), Pentose and glucuronate interconversions (hsa00040), Pyruvate metabolism (hsa00620), Retinol metabolism (hsa00830), Glycolysis / Gluconeogenesis (hsa00010), and Starch and sucrose metabolism (hsa00500).

DISCUSSION {#s3}
==========

Recent studies reported the involvement of immune and metabolic KEGG pathways and GO categories in AD in European population \[[@R6], [@R8]\]. Evidence shows that the human genes may be differentially expressed in different ethnic populations \[[@R14]\]. Here, we investigated the potential mechanisms of these pathways in AD by a pathway analysis of a genome-wide expression dataset in European population \[[@R15]\]. In this pathway analysis, we analyzed all the differentially expressed genes, up-regulated genes and down-regulated genes \[[@R16]\]. It is reported that the analyzing the up- regulated genes and down-regulated genes is more powerful than analyzing all differentially expressed genes \[[@R16]\]. Using the differently expressed AD genes, we identified significantly enriched KEGG pathways related to metabolism and immune processes. Using the up-regulated and down-regulated AD gene list, we further found up-regulated AD genes were significantly enriched in immune and metabolic pathways. We further compare the immune and metabolic KEGG pathways from the expression dataset with those from previous GWAS datasets, and found that most of these pathways are shared in both GWAS and expression datasets.

Interestingly, the clinical studies supported the involvement of immune and metabolic processes in AD, such as disrupted energy metabolism \[[@R17]-[@R20]\], and dysregulation of iron metabolism \[[@R21]\], lipid metabolism \[[@R22]\], phosphoinositides and phosphatidic acid in AD \[[@R22]\], cerebellar glucose metabolism \[[@R23]\], hippocampal metabolism \[[@R24]\], and cerebral metabolism \[[@R25]\]. Take the Natural killer cell mediated cytotoxicity (hsa04650) for example. It is shared in the GWAS and expression datasets. Natural killer cells play an important role in host defence, and are involved in AD immunopathogenesis \[[@R26]\]. The increased natural killer cell cytotoxicity in AD may involve protein kinase C dysregulation \[[@R27]\]. Take the Oxidative phosphorylation (hsa00190) for example. Oxidative phosphorylation could influence clinical status and neuroimaging intermediates in AD \[[@R28]\], and involve early mitochondrial dysfunction and oxidative damage in AD \[[@R29]\]. In summary, our results show that the different expression of genes in immune and metabolic pathways may be associated with AD susceptibility. Our findings may offer new avenues for developing therapeutics for AD by regulating the expression of genes in these immune and metabolic pathways.

Meanwhile, some limitations exist in our research. Here, we performed the pathway analysis of AD expression data using the KEGG database and did not selected the GO categories, considering the difference between KEGG and GO databases \[[@R6], [@R8]\]. Here, we selected only 41 samples from the human temporal cortex tissue. In future, we will select more large-scale sample size and more brain regions to evaluate our findings, and further compare these findings with those from GO database.

MATERIALS AND METHODS {#s4}
=====================

AD expression dataset {#s4_1}
---------------------

The expression dataset came from a whole genome AD case-control expression study (*n* = 41, 25 cases and 16 controls) using human temporal cortex tissue \[[@R15]\]. 25 AD cases and 16 controls were well-matched for age and postmortem delay \[[@R15]\]. We got 1196 significantly differently expressed Affymetrix transcripts with *P* \< 0.05 after false discovery rate (FDR) correction \[[@R15]\].

Dataset preprocessing {#s4_2}
---------------------

In this expression dataset, the 1196 significantly differently expressed transcripts correspond to 1361 unique genes. 1179 of 1361 genes were successfully mapped to 1179 unique Entrez Gene IDs in WebGestalt database \[[@R30]\]. Other 182 genes were mapped to multiple Entrez Gene IDs or could not be mapped to any Entrez Gene ID. The following pathway analysis of all the differently expressed genes will be based upon the 1179 unique genes.

The total of 1196 significantly differently expressed transcripts include 603 significantly up-regulated (AD cases *vs*. controls) and 593 significantly down-regulated (AD cases *vs*. controls) transcripts, which correspond to 710 and 654 unique genes (3 transcripts are both up- and down-regulated in AD cases and controls). 599 of 710 up-regulated genes were successfully mapped to 599 unique Entrez Gene IDs in WebGestalt database \[[@R30]\]. Other 111 genes were mapped to multiple Entrez Gene IDs or could not be mapped to any Entrez Gene ID. The following pathway analysis of up-regulated genes will be based upon the 599 unique genes. 580 of 654 up-regulated genes were successfully mapped to 580 unique Entrez Gene IDs in WebGestalt database \[[@R30]\]. Other 74 genes were mapped to multiple Entrez Gene IDs or could not be mapped to any Entrez Gene ID. The following pathway analysis of down-regulated genes will be based upon the 580 unique genes.

Pathway-based test {#s4_3}
------------------

We selected the WebGestalt database for pathway analysis, and the hypergeometric test was used to identify the significant KEGG pathways \[[@R30]\]. We first conducted a pathway analysis using all the differently expressed AD genes, significantly up-regulated (AD cases *vs*. controls) and down-regulated genes (AD cases *vs*. controls). We selected KEGG pathways including 10-300 genes for subsequent pathway analysis \[[@R31]\]. The entire Entrez gene set was defined to be the reference gene list \[[@R30]\]. We limited potential KEGG pathways with least AD risk 5 genes and with FDR adjusted *p*-value below 0.05 \[[@R30]\].

Supplementary Material {#s5}
======================

We thank Tan et al. for the expression dataset. This work was supported by funding from the National Nature Science Foundation of China (ID: 81471326).

**CONFLICTS OF INTERESTS**

The authors declare no competing financial interests.

**Author Contributions**

J.C., C.C.X., H.Y.Z., and L.F.Y. conceived and initiated the project. J.C., C.C.X., H.Y.Z. analyzed the data. Z.Y.L. and P.P.X. prepared the Tables. J.C., C.C.X., H.Y.Z., Z.Y.L., P.P.X. and L.F.Y. wrote the manuscript. All authors reviewed the manuscript, and contributed to the final manuscript.
